Accelerate Diagnostics Inc  

(Public, NASDAQ:AXDX)   Watch this stock  
Find more results for NYSEAMEX:AXK
8.60
+0.35 (4.24%)
May 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.06 - 8.60
52 week 2.25 - 8.99
Open 8.06
Vol / Avg. 54,024.00/54,530.00
Mkt cap 217.85M
P/E     -
Div/yield     -
EPS -0.46
Shares 25.33M
Beta 1.19
Inst. own 22%

Key stats and ratios

Q4 (Oct '12) 2012
Net profit margin -20060.84% -2251.06%
Operating margin -20201.93% -2268.56%
EBITD margin - -1335.09%
Return on average assets -40.38% -45.24%
Return on average equity -47.24% -54.05%
Employees 6 -
Carbon Disclosure Rating - -

Address

SUITE 108, 303 E 17TH AVE
DENVER, CO 80221
United States - Map
+1-303-8638088 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Accelerate Diagnostics, Inc., formerly Accelr8 Technology Corporation, is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company focuses on the development of a rapid diagnostic platform, the BACcel system, intended for rapid diagnosis in life-threatening bacterial infections. The BACcel system applies its technology to eliminate bacterial culturing, thus eliminating the source of delay with testing methods. The Company�s BACcel system uses bacteriological testing principles, but applies the Company's technology to adapt them to analyze live bacteria extracted directly from a patient specimen. The instrumentation uses automated digital microscopy to measure the responses of extracted live bacterial cells to various test conditions.

Officers and directors

John Patience Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Lawrence Mehren President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Steve Reichling Chief Financial Officer
Age: 34
Bio & Compensation  - Reuters
Thomas V. Geimer Director
Age: 65
Bio & Compensation  - Reuters
Frank J. M. ten Brink Director
Age: 56
Bio & Compensation  - Reuters
Jack W. Schuler Independent Director
Age: 72
Bio & Compensation  - Reuters
Matthew W. Strobeck Ph.D. Independent Director
Age: 39
Bio & Compensation  - Reuters